ATE244579T1 - Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren - Google Patents
Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumorenInfo
- Publication number
- ATE244579T1 ATE244579T1 AT98902634T AT98902634T ATE244579T1 AT E244579 T1 ATE244579 T1 AT E244579T1 AT 98902634 T AT98902634 T AT 98902634T AT 98902634 T AT98902634 T AT 98902634T AT E244579 T1 ATE244579 T1 AT E244579T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- tissue factor
- coagulation
- treatment
- tumors
- Prior art date
Links
- 102000002262 Thromboplastin Human genes 0.000 title abstract 6
- 108010000499 Thromboplastin Proteins 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000015271 coagulation Effects 0.000 title abstract 2
- 238000005345 coagulation Methods 0.000 title abstract 2
- 108010054265 Factor VIIa Proteins 0.000 abstract 3
- 229940012414 factor viia Drugs 0.000 abstract 3
- 239000012190 activator Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 239000000701 coagulant Substances 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 229940051026 immunotoxin Drugs 0.000 abstract 1
- 239000002596 immunotoxin Substances 0.000 abstract 1
- 231100000608 immunotoxin Toxicity 0.000 abstract 1
- 230000002637 immunotoxin Effects 0.000 abstract 1
- 238000007910 systemic administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3592097P | 1997-01-22 | 1997-01-22 | |
| US3620597P | 1997-01-27 | 1997-01-27 | |
| US4242797P | 1997-03-27 | 1997-03-27 | |
| PCT/US1998/001012 WO1998031394A2 (en) | 1997-01-22 | 1998-01-20 | Tissue factor methods and compositions for coagulation and tumor treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE244579T1 true ATE244579T1 (de) | 2003-07-15 |
Family
ID=27364921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98902634T ATE244579T1 (de) | 1997-01-22 | 1998-01-20 | Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US6132730A (de) |
| EP (1) | EP0988056B1 (de) |
| JP (1) | JP2002514201A (de) |
| KR (1) | KR100565883B1 (de) |
| CN (1) | CN100333796C (de) |
| AT (1) | ATE244579T1 (de) |
| AU (1) | AU735187C (de) |
| BR (1) | BR9806793A (de) |
| CA (1) | CA2278106C (de) |
| CY (1) | CY2416B1 (de) |
| DE (1) | DE69816297T9 (de) |
| ES (1) | ES2197458T3 (de) |
| IL (1) | IL130908A0 (de) |
| NO (1) | NO323702B1 (de) |
| NZ (1) | NZ336720A (de) |
| PT (1) | PT988056E (de) |
| WO (1) | WO1998031394A2 (de) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| ATE244579T1 (de) | 1997-01-22 | 2003-07-15 | Univ Texas | Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren |
| US20050260177A1 (en) * | 1998-06-05 | 2005-11-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| US20020172678A1 (en) * | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
| US7264801B2 (en) * | 1998-08-11 | 2007-09-04 | Genentech, Inc. | EG-VEGF nucleic acids and polypeptides and method of use |
| DE69941031D1 (de) * | 1998-11-12 | 2009-08-06 | Novolytics Inc | Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion |
| WO2000069460A1 (en) * | 1999-05-14 | 2000-11-23 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| US20030143233A1 (en) * | 1999-06-07 | 2003-07-31 | Neorx Corporation | Streptavidin expressed gene fusions and methods of use thereof |
| US20030103948A1 (en) * | 1999-06-07 | 2003-06-05 | Neorx Corporation | Streptavidin expressed gene fusions and methods of use thereof |
| US7144991B2 (en) | 1999-06-07 | 2006-12-05 | Aletheon Pharmaceuticals, Inc. | Streptavidin expressed gene fusions and methods of use thereof |
| US6924359B1 (en) * | 1999-07-01 | 2005-08-02 | Yale University | Neovascular-targeted immunoconjugates |
| EP1198479B1 (de) * | 1999-07-01 | 2008-06-18 | Yale University | Neovaskulär gerichtete immunkonjugate |
| US6693176B1 (en) * | 1999-07-23 | 2004-02-17 | University Of Massachusetts | Antitumor antibodies, proteins, and uses thereof |
| CA2378182C (en) * | 1999-07-28 | 2014-09-23 | Genentech, Inc. | Compositions and methods for the treatment of tumors |
| US7217554B2 (en) | 1999-08-31 | 2007-05-15 | Novozymes A/S | Proteases and variants thereof |
| NZ517409A (en) | 1999-08-31 | 2004-05-28 | Novozymes As | RP-II properties with amino acid substitutions used in detergent compositions and additives |
| US6905683B2 (en) | 2000-05-03 | 2005-06-14 | Novo Nordisk Healthcare A/G | Human coagulation factor VII variants |
| CN1447696A (zh) | 2000-05-19 | 2003-10-08 | 杰南技术公司 | 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
| TWI317285B (en) * | 2000-07-28 | 2009-11-21 | Dainippon Sumitomo Pharma Co | New use and kit for remedies for cancer |
| RU2326126C2 (ru) | 2000-09-13 | 2008-06-10 | Ново Нордиск Хелт Кэр Аг | Полипептид фактора vii свертывания крови, его получение и применение |
| AU2002218029A1 (en) | 2000-11-09 | 2002-05-21 | The Scripps Research Institute | Modified factor viia |
| US7622437B2 (en) * | 2000-11-20 | 2009-11-24 | The Board Of Trustees Of The University Of Illinois | Tissue factor compositions and methods |
| US20040002450A1 (en) * | 2000-12-29 | 2004-01-01 | Janette Lazarovits | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| US20040001822A1 (en) * | 2000-12-29 | 2004-01-01 | Avigdor Levanon | Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| US20040001839A1 (en) * | 2000-12-29 | 2004-01-01 | Avigdor Levanon | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| NZ527173A (en) * | 2000-12-29 | 2006-03-31 | Savient Pharmaceuticals Inc | Specific human antibodies for selective cancer therapy |
| US7132510B2 (en) * | 2000-12-29 | 2006-11-07 | Bio-Technology General (Israel) Ltd. | Specific human antibodies for selective cancer therapy |
| TWI233359B (en) * | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
| TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
| US7419949B2 (en) * | 2001-07-16 | 2008-09-02 | Novo Noridsk Healthcare A/G | Single-dose administration of factor VIIa |
| US7052868B2 (en) | 2001-09-27 | 2006-05-30 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
| US20030211075A1 (en) * | 2001-09-27 | 2003-11-13 | Thorpe Philip E. | Combined compositions for tumor vasculature coagulation and treatment |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
| WO2003035688A2 (en) * | 2001-10-26 | 2003-05-01 | Novartis Pharma Gmbh | Targeted thrombosis by tissue factor polypeptides |
| US6960657B2 (en) | 2001-11-02 | 2005-11-01 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
| WO2003054146A2 (en) * | 2001-11-14 | 2003-07-03 | Northwestern University | Self-assembly and mineralization of peptide-amphiphile nanofibers |
| CA2472111A1 (en) * | 2002-01-03 | 2003-07-17 | Tanox, Inc. | Human mast cell-expressed membrane proteins |
| WO2003070749A2 (en) * | 2002-02-15 | 2003-08-28 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
| US20040102402A1 (en) * | 2002-11-22 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of tissue factor expression |
| WO2005014775A2 (en) * | 2002-06-28 | 2005-02-17 | University Of Florida Research Foundation, Inc. | Raav compositions and methods for delivery of human factor vii polypeptides and treatment of hemophilia a |
| US20040208877A1 (en) * | 2002-07-01 | 2004-10-21 | Avigdor Levanon | Antibodies and uses thereof |
| US20040202665A1 (en) * | 2002-07-01 | 2004-10-14 | Janette Lazarovits | Compositions and methods for therapeutic treatment |
| US7572442B2 (en) | 2002-07-15 | 2009-08-11 | Board Of Regents, The University Of Texas System | Selected antibody compositions for binding to aminophospholipids |
| US7534761B1 (en) | 2002-08-21 | 2009-05-19 | North Western University | Charged peptide-amphiphile solutions and self-assembled peptide nanofiber networks formed therefrom |
| US6911323B2 (en) | 2002-09-25 | 2005-06-28 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
| US7554021B2 (en) * | 2002-11-12 | 2009-06-30 | Northwestern University | Composition and method for self-assembly and mineralization of peptide amphiphiles |
| US7683025B2 (en) * | 2002-11-14 | 2010-03-23 | Northwestern University | Synthesis and self-assembly of ABC triblock bola peptide amphiphiles |
| US20040115204A1 (en) * | 2002-12-11 | 2004-06-17 | Fanger Gary R. | Antibodies to treat cancer |
| MXPA05008483A (es) | 2003-02-11 | 2006-03-10 | Univ Northwestern | Metodos y materiales para revestimientos de superficie nanocristalinos y union de nanofibras de anfililos peptidicos sobre las mismas. |
| DK2085470T3 (da) * | 2003-03-20 | 2012-08-06 | Bayer Healthcare Llc | FVII- eller FVIIa-varianter |
| ES2333598T5 (es) * | 2003-05-06 | 2013-09-04 | Biogen Idec Hemophilia Inc | Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia. |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US20070207158A1 (en) * | 2003-06-17 | 2007-09-06 | Harrison Roger G | Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof |
| US20110002978A1 (en) | 2003-06-17 | 2011-01-06 | Harrison Roger G | Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof |
| US20050069955A1 (en) * | 2003-06-30 | 2005-03-31 | Daniel Plaksin | Antibodies and uses thereof |
| US20050152906A1 (en) * | 2003-06-30 | 2005-07-14 | Avigdor Levanon | Specific human antibodies |
| WO2005040187A2 (en) * | 2003-08-06 | 2005-05-06 | Hans Prydz | The use of sirna silencing in the prevention of metastasis |
| DE10338733A1 (de) * | 2003-08-22 | 2005-03-24 | Berdel, Wolfgang E., Prof. Dr.med. | Fusionspolypeptide und deren Verwendung für die antivaskuläre Tumortherapie |
| EP2392655A3 (de) | 2003-09-09 | 2012-02-29 | Novo Nordisk Health Care AG | Gerinnungsfaktor VII Polypeptide |
| WO2005056576A2 (en) | 2003-12-05 | 2005-06-23 | Northwestern University | Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof |
| ATE541580T1 (de) | 2003-12-05 | 2012-02-15 | Univ Northwestern | Selbst anordnende peptid-amphiphile und relevante verfahren für die abgabe von wachstumsfaktor |
| JP4943161B2 (ja) * | 2003-12-23 | 2012-05-30 | ジェネンテック， インコーポレイテッド | 新規抗ｉｌ１３モノクローナル抗体での癌の処置 |
| US20060078542A1 (en) * | 2004-02-10 | 2006-04-13 | Mah Cathryn S | Gel-based delivery of recombinant adeno-associated virus vectors |
| WO2005089398A2 (en) * | 2004-03-18 | 2005-09-29 | St. Luke's Hospital | Method for the delivery of sustained release agents |
| US7556150B2 (en) * | 2004-06-07 | 2009-07-07 | Duramed Pharmaceuticals, Inc. | Dispenser for progestin used for acute and maintenance treatment of DUB |
| US7442778B2 (en) | 2004-09-24 | 2008-10-28 | Amgen Inc. | Modified Fc molecules |
| EP1812032A4 (de) * | 2004-10-27 | 2009-09-02 | Univ Illinois | Gewebefaktorzusammensetzung und verfahren |
| CA2598251A1 (en) * | 2005-03-04 | 2006-09-14 | Northwestern University | Angiogenic heparin binding peptide amphiphiles |
| US7393833B2 (en) * | 2005-03-09 | 2008-07-01 | The Board Of Regents Of The University Of Oklahoma | Chimeric proteins with phosphatidylserine binding domains |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| US8076295B2 (en) * | 2007-04-17 | 2011-12-13 | Nanotope, Inc. | Peptide amphiphiles having improved solubility and methods of using same |
| GB0723712D0 (en) * | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
| NZ588587A (en) | 2008-03-19 | 2013-01-25 | China Synthetic Rubber Corp | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
| AU2010210141A1 (en) * | 2009-02-05 | 2011-09-01 | Pierre Philippart | Method and means for producing tissues and tissues obtained |
| AU2010236584A1 (en) * | 2009-04-13 | 2011-11-10 | Northwestern University | Novel peptide-based scaffolds for cartilage regeneration and methods for their use |
| CN102153653B (zh) * | 2010-12-30 | 2012-08-15 | 厦门大学 | 肿瘤血管靶向多肽与组织因子的融合蛋白及其制备方法 |
| RU2016107435A (ru) | 2013-09-13 | 2017-10-18 | Дженентек, Инк. | Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты |
| EP3683232A1 (de) | 2013-09-13 | 2020-07-22 | F. Hoffmann-La Roche AG | Verfahren und zusammensetzungen mit gereinigten rekombinanten polypeptiden |
| US9493552B2 (en) * | 2013-11-15 | 2016-11-15 | China Synthetic Rubber Corporation | Therapeutic biologic for treatment of hepatocellular carcinoma |
| US9987241B2 (en) | 2014-09-25 | 2018-06-05 | The Board Of Regents Of The University Of Oklahoma | Enzyme conjugate and prodrug cancer therapy |
| CN104387474B (zh) * | 2014-11-17 | 2018-01-23 | 北京华安科创生物技术有限公司 | 一种肿瘤血管梗塞剂多肽、基因、表达载体及其应用 |
| CN106699875A (zh) * | 2017-02-23 | 2017-05-24 | 青岛古高生物科技有限公司 | 一种人重组组织因子及其基因、表达载体、宿主菌和表达方法 |
| WO2020032951A1 (en) | 2018-08-09 | 2020-02-13 | The Board Of Regents Of The University Of Oklahoma | Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same |
| CN108948209A (zh) * | 2018-07-17 | 2018-12-07 | 广西医科大学 | 一种cd105单链抗体-es融合蛋白的制备方法和用途 |
| CN109999182B (zh) * | 2019-03-29 | 2023-03-07 | 四川大学华西医院 | 凝血因子在制备抗肿瘤药物中的应用 |
| AU2024372189A1 (en) * | 2023-10-31 | 2026-03-05 | Immunitybio, Inc. | Multi-chain chimeric polypeptides and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0086627B1 (de) * | 1982-02-12 | 1985-08-28 | Unitika Ltd. | Antikrebsmittel |
| GB2197321B (en) | 1986-09-12 | 1990-10-03 | Genentech Inc | Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line |
| ES2073391T3 (es) | 1986-11-04 | 1995-08-16 | Genentech Inc | Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre. |
| US5017556A (en) * | 1986-11-04 | 1991-05-21 | Genentech, Inc. | Treatment of bleeding disorders using lipid-free tissue factor protein |
| US5589173A (en) * | 1986-11-04 | 1996-12-31 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
| IE81149B1 (en) | 1987-02-12 | 2000-05-03 | Genentech Inc | Methods and deoxyribonucleic acid for the preparation of tissue factor protein |
| US5110730A (en) * | 1987-03-31 | 1992-05-05 | The Scripps Research Institute | Human tissue factor related DNA segments |
| US5437864A (en) * | 1987-03-31 | 1995-08-01 | The Scripps Research Institute | Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor |
| US6001978A (en) | 1987-03-31 | 1999-12-14 | The Scripps Research Institute | Human tissue factor related DNA segments polypeptides and antibodies |
| US5223427A (en) * | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| US5147638A (en) | 1988-12-30 | 1992-09-15 | Oklahoma Medical Research Foundation | Inhibition of tumor growth by blockade of the protein C system |
| US5472850A (en) | 1991-04-10 | 1995-12-05 | Oklahoma Medical Research Foundation | Quantitative clotting assay for activated factor VII |
| US5134075A (en) | 1989-02-17 | 1992-07-28 | Oncogen Limited Partnership | Monoclonal antibody to novel antigen associated with human tumors |
| US5314695A (en) * | 1990-11-13 | 1994-05-24 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
| US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
| US5374617A (en) * | 1992-05-13 | 1994-12-20 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with FVIIa |
| US5346991A (en) * | 1991-06-13 | 1994-09-13 | Genentech, Inc. | Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders |
| WO1993009804A1 (en) * | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation |
| WO1993017715A1 (en) * | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
| AU5093593A (en) * | 1992-08-28 | 1994-03-29 | Scripps Research Institute, The | Inhibition of tumor metastasis via neutralization of tissue factor function |
| WO1994007515A1 (en) * | 1992-10-06 | 1994-04-14 | The Scripps Research Institute | Mutant tissue factor lacking factor vii activation activity |
| DK1975181T3 (da) | 1992-10-28 | 2011-06-06 | Genentech Inc | Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister |
| US5726147A (en) * | 1993-06-01 | 1998-03-10 | The Scripps Research Institute | Human mutant tissue factor compositions useful as tissue factor antagonists |
| US5830448A (en) | 1994-06-16 | 1998-11-03 | Genentech, Inc. | Compositions and methods for the treatment of tumors |
| EP0771216B9 (de) * | 1994-07-11 | 2003-01-02 | The Board Of Regents, The University Of Texas System | Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen |
| US5583267B1 (en) * | 1995-01-27 | 1998-11-24 | Enzymol International | Biocatalytic process for preparing tetraalkylbiphenols |
| US5922688A (en) | 1997-01-10 | 1999-07-13 | Board Of Regents, The University Of Texas System | PEA3 is a tumor suppressor |
| ATE244579T1 (de) | 1997-01-22 | 2003-07-15 | Univ Texas | Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren |
| WO1998052572A1 (en) | 1997-05-22 | 1998-11-26 | Oklahoma Medical Research Foundation | Use of taurolidine for treatment of leukemias |
| US7740841B1 (en) | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
-
1998
- 1998-01-20 AT AT98902634T patent/ATE244579T1/de not_active IP Right Cessation
- 1998-01-20 NZ NZ336720A patent/NZ336720A/en unknown
- 1998-01-20 US US09/009,656 patent/US6132730A/en not_active Expired - Fee Related
- 1998-01-20 ES ES98902634T patent/ES2197458T3/es not_active Expired - Lifetime
- 1998-01-20 EP EP98902634A patent/EP0988056B1/de not_active Expired - Lifetime
- 1998-01-20 IL IL13090898A patent/IL130908A0/xx not_active IP Right Cessation
- 1998-01-20 PT PT98902634T patent/PT988056E/pt unknown
- 1998-01-20 JP JP53463098A patent/JP2002514201A/ja active Pending
- 1998-01-20 AU AU59243/98A patent/AU735187C/en not_active Ceased
- 1998-01-20 WO PCT/US1998/001012 patent/WO1998031394A2/en not_active Ceased
- 1998-01-20 US US09/009,217 patent/US6132729A/en not_active Expired - Fee Related
- 1998-01-20 CA CA002278106A patent/CA2278106C/en not_active Expired - Fee Related
- 1998-01-20 BR BR9806793-1A patent/BR9806793A/pt not_active Application Discontinuation
- 1998-01-20 DE DE69816297T patent/DE69816297T9/de active Active
- 1998-01-20 KR KR1019997006622A patent/KR100565883B1/ko not_active Expired - Fee Related
- 1998-01-20 CN CNB988034336A patent/CN100333796C/zh not_active Expired - Fee Related
- 1998-01-20 US US09/009,822 patent/US6156321A/en not_active Expired - Fee Related
-
1999
- 1999-07-21 NO NO19993567A patent/NO323702B1/no unknown
-
2000
- 2000-05-18 US US09/573,835 patent/US7951356B1/en not_active Expired - Fee Related
-
2003
- 2003-02-27 US US10/375,741 patent/US7101557B2/en not_active Expired - Fee Related
- 2003-10-07 CY CY0300067A patent/CY2416B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US6132730A (en) | 2000-10-17 |
| AU5924398A (en) | 1998-08-07 |
| US6132729A (en) | 2000-10-17 |
| NZ336720A (en) | 2001-06-29 |
| WO1998031394A2 (en) | 1998-07-23 |
| CA2278106A1 (en) | 1998-07-23 |
| CN100333796C (zh) | 2007-08-29 |
| BR9806793A (pt) | 2000-05-16 |
| PT988056E (pt) | 2003-09-30 |
| WO1998031394A3 (en) | 1998-09-17 |
| AU735187C (en) | 2002-04-18 |
| US7101557B2 (en) | 2006-09-05 |
| NO993567D0 (no) | 1999-07-21 |
| US20030232753A1 (en) | 2003-12-18 |
| EP0988056B1 (de) | 2003-07-09 |
| DE69816297D1 (de) | 2003-08-14 |
| NO993567L (no) | 1999-09-21 |
| DE69816297T2 (de) | 2003-12-24 |
| US7951356B1 (en) | 2011-05-31 |
| CA2278106C (en) | 2005-04-12 |
| JP2002514201A (ja) | 2002-05-14 |
| DE69816297T9 (de) | 2004-09-09 |
| CN1251532A (zh) | 2000-04-26 |
| KR20000070389A (ko) | 2000-11-25 |
| CY2416B1 (en) | 2004-11-12 |
| US6156321A (en) | 2000-12-05 |
| NO323702B1 (no) | 2007-06-25 |
| EP0988056A2 (de) | 2000-03-29 |
| IL130908A0 (en) | 2001-01-28 |
| KR100565883B1 (ko) | 2006-03-31 |
| ES2197458T3 (es) | 2004-01-01 |
| AU735187B2 (en) | 2001-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69816297D1 (de) | Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren | |
| NO20015584L (no) | Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling | |
| ID24901A (id) | Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh | |
| DE69931766D1 (de) | Antitumorale mittel | |
| TR199903331T2 (xx) | Farnesil protein transferas engelleyicileri. | |
| MX9606386A (es) | Agentes que afectan la hemostasis trombotica. | |
| DE69621012D1 (de) | VERWENDUNG VON NSAIDs ZUR BEHANDLUNG VON PLATTENEPITHELKARZINOM DER MUNDHÖHLE UND KEHLKOPF | |
| ATE230614T1 (de) | Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten | |
| DK1289517T3 (da) | Farmaceutiske sammensætninger indeholdende cannabidiolderivater | |
| ATE324907T1 (de) | Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen | |
| CY1110113T1 (el) | Φωσφολιπιδιου παραγωγα βαλπροϊκου οξεος και μειγματα αυτων | |
| WO2003028840A3 (en) | Combined compositions and methods for tumor vasculature coagulation and treatment | |
| DK0642352T3 (da) | Afkortet vævsfaktor og FVIIa- eller FVII-aktivator til blodkoagulation | |
| ATE319447T1 (de) | Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen | |
| GEP20012448B (en) | Tissue Plasminogen Activators (Improved Variants) | |
| HUP0102039A2 (hu) | Albuminnal stabilizált paclitaxel alkalmazása tömör tumorok kezelésére szolgáló gyógyszerkészítmények előállítására, és a kapott gyógyszerkészítmények | |
| UA70919C2 (uk) | Композиція для лікування та запобігання артеріальному тромбозу з використанням інгібітора фактора ха окремо або в комбінації з препаратом, що унеможливлює агрегацію тромбоцитів | |
| ATE461707T1 (de) | Pharmazeutische verbindung und methoden zur behandlungen von menschliche karzinome mittels arginin entzug | |
| EA200200922A1 (ru) | Композиция, включающая камптотецин и производное пиримидина, для лечения рака | |
| BR9814419A (pt) | "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas" | |
| MY118986A (en) | Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia | |
| UA72927C2 (uk) | Композиція для лікування печінково-клітинного раку, що містить доцетаксель | |
| DE60222383D1 (de) | Medikament zur verabreichung von amifostin und verwandten wirkstoffen | |
| AP1896A (en) | The method of treating cancer | |
| WO2001041747A3 (de) | Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0988056 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |